269 related articles for article (PubMed ID: 21108610)
1. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus.
Semiz S; Dujic T; Ostanek B; Prnjavorac B; Bego T; Malenica M; Marc J; Causevic A
Bosn J Basic Med Sci; 2010 Nov; 10(4):287-91. PubMed ID: 21108610
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population.
Arvanitidis K; Ragia G; Iordanidou M; Kyriaki S; Xanthi A; Tavridou A; Manolopoulos VG
Fundam Clin Pharmacol; 2007 Aug; 21(4):419-26. PubMed ID: 17635181
[TBL] [Abstract][Full Text] [Related]
3. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
[TBL] [Abstract][Full Text] [Related]
4. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
6. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
[TBL] [Abstract][Full Text] [Related]
7. Applications of CYP450 testing in the clinical setting.
Samer CF; Lorenzini KI; Rollason V; Daali Y; Desmeules JA
Mol Diagn Ther; 2013 Jun; 17(3):165-84. PubMed ID: 23588782
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions--a pilot study.
Egger T; Dormann H; Ahne G; Pahl A; Runge U; Azaz-Livshits T; Neubert A; Criegee-Rieck M; Gassmann KG; Brune K
Drugs Aging; 2005; 22(3):265-72. PubMed ID: 15813658
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales.
Sistonen J; Fuselli S; Palo JU; Chauhan N; Padh H; Sajantila A
Pharmacogenet Genomics; 2009 Feb; 19(2):170-9. PubMed ID: 19151603
[TBL] [Abstract][Full Text] [Related]
12. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
15. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
[TBL] [Abstract][Full Text] [Related]
16. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations.
Zuo LJ; Guo T; Xia DY; Jia LH
Genet Test Mol Biomarkers; 2012 Feb; 16(2):102-8. PubMed ID: 22224559
[TBL] [Abstract][Full Text] [Related]
17. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
18. [CYP2D6-, CYP2C9- and CYP2C19-based dose adjustments: when do they make sense?].
Seeringer A; Kirchheiner J
Internist (Berl); 2008 Jul; 49(7):877-83. PubMed ID: 18551264
[TBL] [Abstract][Full Text] [Related]
19. Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It mutation detection assays.
Melis R; Lyon E; McMillin GA
Expert Rev Mol Diagn; 2006 Nov; 6(6):811-20. PubMed ID: 17140368
[TBL] [Abstract][Full Text] [Related]
20. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics.
Kirchheiner J; Müller G; Meineke I; Wernecke KD; Roots I; Brockmöller J
J Clin Psychopharmacol; 2003 Oct; 23(5):459-66. PubMed ID: 14520122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
